| ²é¿´: 164 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
Âó¶µ1836ͳæ (СÓÐÃûÆø)
|
[½»Á÷]
¼±ÇóÒ»¶ÎСÎÄ×ֵķÒë
|
||
|
We enrolled 189 patients with active RA despite methotrexate therapy in a 3-month, multicenter, ascending-dose, double-blind, placebo-controlled trial. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) re- sponse rate at week 12. |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ£¬³õÊԳɼ¨350Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ4È˻ظ´
323·Ö£¨¼ÆËã»úÊÓ¾õºÍ´óÄ£ÐÍÏîÄ¿£©ÄÜÖ±½ÓÉÏÊÖ
ÒѾÓÐ3È˻ظ´
311·Ö 22408 Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Ö£´ó0705Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§
ÒѾÓÐ10È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ11È˻ظ´
wsshihan
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
ÜòÉñ
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 1.6
- ½ð±Ò: 5983.8
- É¢½ð: 520
- ºì»¨: 2
- Ìû×Ó: 2332
- ÔÚÏß: 128.4Сʱ
- ³æºÅ: 98932
- ×¢²á: 2005-11-11
- ÐÔ±ð: GG
- רҵ: ¶ù¿Æ¡¢ÑªÒº¡¢Ô¤·À
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
zap65535(½ð±Ò+6,VIP+0):²¹·¢ 12-22 11:19
zap65535(½ð±Ò+6,VIP+0):²¹·¢ 12-22 11:19
|
ÎÒÃǵǼÇÁË189¸ö¾3¸öÔ¶àÖÐÐÄ¡¢ÉÏÐÐ-¼ÁÁ¿¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕ¡¢¼×°±µûßÊÖÎÁƵĴ¦ÓڻÆÚRA»¼Õß¡£ÊÔÑéÖ÷ÒªÖÕµãΪÔÚµÚ12ÖܵÄÃÀ¹ú·çʪ²¡Ñ§»á20%¸ÄÉÆ±ê×¼(ACR20)·´Ó¦ÂÊ¡£ [ Last edited by wsshihan on 2009-10-11 at 15:04 ] |

2Â¥2009-10-11 14:59:11














»Ø¸´´ËÂ¥
5